NEW YORK, June 11 – Canada’s Virtek Vision International said Monday that its Virtek ChipWriter and Virtek ChipReader had been selected for a six-month trial to apply its microarray technology for a neonatal screening application.

Under the terms of the alliance, Virtek has agreed to supply its spotter and reader to Neo Gen Screening and TeleChem International/ArrayIt.com for the testing of metabolic disorders in newborns. TeleChem of Sunnyvale, Calif., has developed the assays while Neo Gen Screening of Pittsburgh, Pa., develops tests for screening disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.